BACKGROUND: The ATM kinase constitutes a master regulatory hub of DNA damage and activates the p53 response pathway by phosphorylating the MDM2 protein, which develops an affinity for the p53 mRNA secondary structure. Disruption of this interaction prevents the activation of the nascent p53. The link of the MDM2 protein-p53 mRNA interaction with the upstream DNA damage sensor ATM kinase and the role of the p53 mRNA in the DNA damage sensing mechanism, are still highly anticipated. METHODS: The proximity ligation assay (PLA) has been extensively used to reveal the sub-cellular localisation of the protein-mRNA and protein-protein interactions. ELISA and co-immunoprecipitation confirmed the interactions in vitro and in cells. RESULTS: This study provides a novel mechanism whereby the p53 mRNA interacts with the ATM kinase enzyme and shows that the L22L synonymous mutant, known to alter the secondary structure of the p53 mRNA, prevents the interaction. The relevant mechanistic roles in the DNA Damage Sensing pathway, which is linked to downstream DNA damage response, are explored. Following DNA damage (double-stranded DNA breaks activating ATM), activated MDMX protein competes the ATM-p53 mRNA interaction and prevents the association of the p53 mRNA with NBS1 (MRN complex). These data also reveal the binding domains and the phosphorylation events on ATM that regulate the interaction and the trafficking of the complex to the cytoplasm. CONCLUSION: The presented model shows a novel interaction of ATM with the p53 mRNA and describes the link between DNA Damage Sensing with the downstream p53 activation pathways; supporting the rising functional implications of synonymous mutations altering secondary mRNA structures.

Department of Medical Biosciences Umeå University Umeå 90185 Sweden

Inserm UMRS1131 Institut de Génétique Moléculaire Paris Cité Université Hôpital St Louis Paris France

Institut de Biotecnologia 1 de Biomedicina Universitat Autònoma de Barcelona Bellaterra Spain

Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czech Republic

Zobrazit více v PubMed

Bian L, Meng Y, Zhang M, Li D. MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Mol Cancer. 2019;18:169. doi: 10.1186/s12943-019-1100-5. PubMed DOI PMC

Stracker TH, Roig I, Knobel PA, Marjanovic M. The ATM signaling network in development and disease. Front Genet. 2013;4:37. doi: 10.3389/fgene.2013.00037. PubMed DOI PMC

Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle. 2010;9:472–478. doi: 10.4161/cc.9.3.10556. PubMed DOI PMC

Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol. 2010;2:a000893. doi: 10.1101/cshperspect.a000893. PubMed DOI PMC

MacLaine NJ, Hupp TR. How phosphorylation controls p53. Cell Cycle. 2011;10:916–921. doi: 10.4161/cc.10.6.15076. PubMed DOI

Karakostis K, Vadivel Gnanasundram S, Lopez I, Thermou A, Wang L, Nylander K, Olivares-Illana V, Fahraeus R. A single synonymous mutation determines the phosphorylation and stability of the nascent protein. J Mol Cell Biol. 2019;11:187–199. doi: 10.1093/jmcb/mjy049. PubMed DOI PMC

Karakostis K, Ponnuswamy A, Fusee LT, Bailly X, Laguerre L, Worall E, Vojtesek B, Nylander K, Fahraeus R. p53 mRNA and p53 protein structures have evolved independently to interact with MDM2. Mol Biol Evol. 2016;33:1280–1292. doi: 10.1093/molbev/msw012. PubMed DOI

Karakostis K, Fahraeus R. Shaping the regulation of the p53 mRNA tumour suppressor: the co-evolution of genetic signatures. BMC Cancer. 2019;19:915. doi: 10.1186/s12885-019-6118-y. PubMed DOI PMC

Zheng S, Kim H, Verhaak RGW. Silent mutations make some noise. Cell. 2014;156:1129–1131. doi: 10.1016/j.cell.2014.02.037. PubMed DOI

Sharma Y, Miladi M, Dukare S, Boulay K, Caudron-Herger M, Gross M, Backofen R, Diederichs S. A pan-cancer analysis of synonymous mutations. Nat Commun. 2019;10:2569. doi: 10.1038/s41467-019-10489-2. PubMed DOI PMC

Teng H, Wei W, Li Q, Xue M, Shi X, Li X, Mao F, Sun Z. Prevalence and architecture of posttranscriptionally impaired synonymous mutations in 8,320 genomes across 22 cancer types. Nucleic Acids Res. 2020;48:1192–1205. doi: 10.1093/nar/gkaa019. PubMed DOI PMC

Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, et al. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 2022;603:335–342. doi: 10.1038/s41586-022-04451-4. PubMed DOI

Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B. Synonymous mutations frequently act as driver mutations in human cancers. Cell. 2014;156:1324–1335. doi: 10.1016/j.cell.2014.01.051. PubMed DOI

Gnanasundram SV, Malbert-Colas L, Chen S, Fusee L, Daskalogianni C, Muller P, Salomao N, Fahraeus R. MDM2's dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities. Nucleic Acids Res. 2020;48:6775–6787. doi: 10.1093/nar/gkaa431. PubMed DOI PMC

Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–1166. doi: 10.1126/science.1140321. PubMed DOI

Warren C, Pavletich NP. Structure of the human ATM kinase and mechanism of Nbs1 binding. Elife. 2022;11:e74218. doi: 10.7554/eLife.74218. PubMed DOI PMC

Poon GYP, Watson CJ, Fisher DS, Blundell JR. Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues. Nat Genet. 2021;53:1597–1605. doi: 10.1038/s41588-021-00957-1. PubMed DOI

Padariya M, Jooste ML, Hupp T, Fahraeus R, Vojtesek B, Vollrath F, Kalathiya U, Karakostis K. The elephant evolved p53 Isoforms that escape MDM2-mediated repression and cancer. Mol Biol Evol. 2022;39:msac149. doi: 10.1093/molbev/msac149. PubMed DOI PMC

Baretic D, Pollard HK, Fisher DI, Johnson CM, Santhanam B, Truman CM, Kouba T, Fersht AR, Phillips C, Williams RL. Structures of closed and open conformations of dimeric human ATM. Sci Adv. 2017;3:e1700933. doi: 10.1126/sciadv.1700933. PubMed DOI PMC

Alexander A, Walker CL. Differential localization of ATM is correlated with activation of distinct downstream signaling pathways. Cell Cycle. 2010;9:3685–3686. doi: 10.4161/cc.9.18.13253. PubMed DOI PMC

Li J, Han YR, Plummer MR, Herrup K. Cytoplasmic ATM in neurons modulates synaptic function. Curr Biol. 2009;19:2091–2096. doi: 10.1016/j.cub.2009.10.039. PubMed DOI PMC

Shah P, McGuigan CW, Cheng S, Vanpouille-Box C, Demaria S, Weiss RS, Lammerding J. ATM modulates nuclear mechanics by regulating lamin A levels. Front Cell Dev Biol. 2022;10:875132. doi: 10.3389/fcell.2022.875132. PubMed DOI PMC